Companies › Acerand Therapeutics (Shanghai)
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ACE-86225106 PARP inhibitor | PARP1, PARP2 | Phase 1 | Solid Tumor, Adult | Dec 2028 |
| ACE-232 | – | Phase 1 | Prostate Cancer (Adenocarcinoma) | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06380660 | ACE-86225106 | Phase 1 | Solid Tumor, Adult | Oncology | Dec 2028 |
| NCT06801236 | ACE-232 | Phase 1 | Prostate Cancer (Adenocarcinoma) | Oncology | Dec 2028 |
AstraZeneca Merck & Co. (MSD) Pfizer Johnson & Johnson (Janssen) GSK Eikon Therapeutics BeiGene Impact Therapeutics pharmaand Allarity Therapeutics
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.